Dongbao Bio-Tech(SZ:300239)2025-07-11 11:34Financial Performance - In 2024, Dongbao Biological's operating revenue was 888.49 million yuan, a decrease of 9.19% year-on-year [5] - The net profit attributable to shareholders was 85.98 million yuan, down 28.28% compared to the previous year [5] - The net cash flow from operating activities was 69.13 million yuan, a decline of 65.33% from 2023 [4] Cost Control and Management Strategies - In 2024, the company enhanced cost control measures, focusing on supply chain management and optimizing procurement strategies [2][3] - The company implemented a strict supplier management system to ensure quality and cost efficiency [2][3] - Emphasis was placed on a "prevention, control, improvement" management philosophy to enhance product quality [3][9] Future Growth and Market Strategy - Dongbao Biological aims to expand its market presence in the health sector, particularly in collagen applications across various industries [10][12] - The company plans to leverage digital transformation to improve operational efficiency and enhance decision-making processes [6][8] - Future initiatives include deepening collaboration with core customers and exploring new market segments, particularly in the aging population market [10][12] Shareholder Returns - The proposed cash dividend for 2024 is 0.25 yuan per 10 shares (including tax), reflecting the company's commitment to shareholder returns while ensuring operational sustainability [9][13] Research and Development Achievements - In 2024, the company made significant progress in the collagen industry, including the development of low-fat cream collagen and specialized collagen for cashmere textiles [7][10] - The company is actively pursuing innovative applications of collagen in health foods and new materials [7][10] Risk Management - Dongbao Biological has identified potential risks in achieving its 2025 performance targets and has outlined corresponding mitigation strategies in its annual report [3]